Cardiff Oncology, Inc.

Cardiff Oncology operates with a capital structure characterized by zero debt and a current ratio of 3.27, indicating strong short-term liquidity coverage relative to liabilities. The company holds $8.5 million in cash and equivalents against total assets of $49.2 million and total liabilities of $14.5 million. However, the firm faces substantial going-concern uncertainty, as management has disclosed that its ability to continue operations depends on obtaining additional equity or debt financing, government grants, or reducing expenditures. The market capitalization stands at approximately $61.7 million, with a price-to-book ratio of 1.78, reflecting investor valuation of tangible assets despite negative earnings.

Profitability metrics are deeply negative, with a return on equity of -1.32 and return on assets of -0.93, driven by an operating income loss of $12.85 million and net income loss of $12.35 million in Q1 2026. The company generated only $41,000 in revenue during the period, resulting in an EV/Revenue multiple of 26.32, which is typical for pre-commercial biotech firms but highlights the absence of scale. Operating cash flow was negative $12.3 million, consistent with the high burn rate associated with clinical-stage development. Without cohort median data for direct comparison, these figures align with the industry norm for early-stage pharmaceutical companies that have not yet achieved commercial product sales.

Revenue concentration is effectively non-existent in terms of commercial product sales, with the $41,000 reported likely stemming from minor licensing or grant activities rather than core product revenue. The company’s business model relies entirely on future clinical success and regulatory approval for its product candidates. There is no disclosed geographic revenue mix, implying that operations are centralized and revenue sources are not diversified by region. The lack of significant revenue streams means the company is not exposed to traditional market demand fluctuations but is highly sensitive to clinical trial outcomes and regulatory milestones.

Growth trajectory is currently defined by capital consumption rather than revenue expansion. The financial snapshot shows a single period of data with negligible revenue and significant losses, indicating that the company is in the investment phase of its lifecycle. Historical periods data is not provided, but the filing observations note that the company has incurred net losses since inception. The path to growth depends on advancing clinical trials, which is hindered by limited capacity for recruiting and managing trials, a key operational risk identified in filings.

Risk factors are elevated, with a medium dilution risk and high liquidity risk flags due to going-concern language. The company is subject to regulatory risks including the Foreign Corrupt Practices Act and the federal Anti-Kickback Statute, which prohibit certain payments to government officials and healthcare providers. Additionally, the stock price fell below $1.00 to $0.8861, triggering a high-severity alert for US continued-listing minimum-bid threshold compliance. This listing risk poses an immediate threat to the company’s ability to raise capital in public markets, potentially forcing a reverse stock split or delisting if not resolved within the 30-day deficiency period.

Recent events highlight the critical nature of the listing deficiency, with the price drop to $0.8861 occurring as of July 15, 2026. Analyst sentiment remains cautiously optimistic, with a mean price target of $7.50 and a mean recommendation of 2.38 (buy), suggesting that the market expects a resolution to the listing issue and potential clinical upside. However, the wide range of price targets ($2.00 to $12.00) reflects significant uncertainty regarding the company’s ability to navigate its financial and regulatory challenges.

Cardiff Oncology, Inc. (CRDF) experienced no material changes in its fundamental profile during the latest review period. The analysis of 17 fields, excluding four schema-expansion items, confirmed that the company's core metrics remained stable relative to prior assessments. This lack of significant movement suggests a period of operational continuity for the biopharmaceutical firm. The primary updates were confined to the internal analytical narrative and conclusions, which were revised with a low similarity score of 0.221. These modifications resulted in a net neutral adjustment to the key takeaways, with five additions and five removals. Despite these textual revisions, the underlying data points driving the analysis did not shift in a way that would alter the company's strategic outlook. Quantitative metrics also showed negligible variation. The company's calculated market share percentage adjusted minutely from 3.6315932521198237e-09 to 3.6315920722843025e-09, representing a 0.0% change. This statistical stability reinforces the conclusion that no significant market dynamics or competitive shifts occurred for CRDF during this interval. The company continues to operate with a lean executive structure, maintaining one officer, while being followed by four analysts. With 22 top holders and no index memberships, CRDF remains a niche holding in the broader market. The absence of new watcher signals or cross-source alerts further indicates that no external events have disrupted the current investment thesis.

Analysts project 850% upside to a mean price target of $8.57, significantly above the current market price of $0.90.

Revenue grew at an 18.3% compound annual growth rate from FY2023 to FY2025, indicating expanding top-line momentum.

The company maintains a low leverage band with a debt-to-equity ratio of 0.36, reducing financial distress risk.

A current ratio of 3.67 suggests strong short-term liquidity coverage relative to immediate obligations.

The company faces high liquidity risk and medium dilution risk, threatening capital stability and shareholder value.

Operating margin of -82.6% ranks in the bottom quartile among 371 biotechnology peers, signaling severe inefficiency.

Net margin of -77.3% places the firm in the bottom quartile of its cohort, reflecting persistent unprofitability.

Return on equity of -1.32% falls in the bottom quartile, indicating poor capital generation for shareholders.

Free cash flow remained deeply negative at -$37.8 million in FY2025, highlighting ongoing cash burn.

Revenue $41.0k; Operating income -$12.8M.

• ▍Revenue $41.0k
• ▍Operating income -$12.8M
• ▍Net margin -30109.8%

Revenue $350.0k; Operating income -$41.1M.

• ▍Revenue $350.0k
• ▍Operating income -$41.1M
• ▍Net margin -11038.6%

Revenue $230.0k; Operating income -$29.2M.

• ▍Revenue $230.0k
• ▍Operating income -$29.2M
• ▍Net margin -11903.0%

Revenue $593.0k; Operating income -$49.0M.

• ▍Revenue $593.0k
• ▍Operating income -$49.0M
• ▍Net margin -7732.0%

Revenue $683.0k; Operating income -$48.7M.

• ▍Revenue $683.0k
• ▍Operating income -$48.7M
• ▍Net margin -6651.7%

Revenue $683.0k; Operating income -$48.7M.

• ▍Revenue $683.0k
• ▍Operating income -$48.7M
• ▍Net margin -6651.7%

Revenue $488.0k; Operating income -$45.4M.

• ▍Revenue $488.0k
• ▍Operating income -$45.4M
• ▍Net margin -8492.0%

Revenue $488.0k; Operating income -$45.4M.

• ▍Revenue $488.0k
• ▍Operating income -$45.4M
• ▍Net margin -8492.0%